# US 2024/0189442 A1 · Targeting conjugates with therapeutic agents and oligonucleotides and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0189442 A1
- Document ID: US20240189442A1
- Status: Published application
- Kind: A1
- Application number: 18/278,784
- Filed: 2022-02-24
- Published: 2024-06-13
- Earliest claimed: 2021-02-25
- Assignees: Allygen Group
- Applicants: Allygen Group
- Inventors: Jun XIANG; Wenlong GAO
- Web page: https://patentgrep.com/patent/US20240189442A1

## CPC

- A61K 47/6849: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
- A61P 35/00: Antineoplastic agents
- A61K 47/549: {Sugars, nucleosides, nucleotides or nucleic acids}
- A61K 47/64: Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65)
- A61K 47/6851: {the antibody targeting a determinant of a tumour cell}
- A61K 47/6889: {Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment}
- C07K 16/2827: {against B7 molecules, e.g. CD80, CD86}
- C07K 16/30: from tumour cells
- C07K 19/00: Hybrid peptides {, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes}
- C07K 2317/31: multispecific
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2319/50: containing protease site
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Provided are targeting conjugates comprising a targeting moiety, a therapeutic agent, and an oligonucleotide, wherein the oligonucleotide is attached to the targeting moiety via a targeting moiety binding fragment (TBF), wherein the therapeutic agent and/or the oligonucleotide can be released from the targeting conjugate via cleavage. Also provided are pharmaceutical compositions and methods of treatment using the targeting conjugates.

## Claims

### Claim at position 1

1-74. (canceled)

### Claim 75

A targeting conjugate comprising a targeting moiety, a therapeutic agent, and an oligonucleotide, wherein the therapeutic agent and/or the oligonucleotide can be released from the targeting conjugate via cleavage.

### Claim 76 (depends on 75)

The targeting conjugate of claim 75, wherein the targeting conjugate comprises the structure of Formula I:
wherein:
A is the targeting moiety;
D is the therapeutic agent;
O is the oligonucleotide;
B is a targeting moiety binding fragment (TBF);
P1 is a first cleavage site;
P2 is a second cleavage site;
C1 is a first conjugation site;
C2 is a second conjugation site;
L1 is a first linker;
L2 is a second linker;
x=0 or 1; u=0 or 1; v=0 or 1;
a=1-20; b=1-20; c=1-20; d=1-20; and e=1-20; and
wherein A optionally comprises a third cleavage site.

### Claim 77 (depends on 75)

The targeting conjugate of claim 75, wherein the cleavage is triggered by a condition at a target site.

### Claim 78 (depends on 77)

The targeting conjugate of claim 77, wherein
i) the target site is a site of a disease; and/or
ii) the condition at the target site is selected from the group consisting of: protease, pH change, redox change, hypoxia, oxidative stress, hyperthermia, and extracellular ATP concentration.

### Claim 79 (depends on 75)

The targeting conjugate of claim 75, wherein the cleavage is by a protease.

### Claim 80 (depends on 76)

The targeting conjugate of claim 76, wherein the TBF comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 74-83, 148-150, and 152.

### Claim 81 (depends on 75)

The targeting conjugate of claim 75, wherein the targeting moiety comprises an anti-PD-L1 antibody or antigen-binding fragment thereof, or an anti-Trop-2 antibody or antigen-binding fragment thereof.

### Claim 82 (depends on 75)

The targeting conjugate of claim 75, wherein the targeting moiety comprises a first targeting peptide or a first antibody or antigen-binding fragment thereof recognizing a first target molecule, and a second targeting peptide or a second antibody or antigen-binding fragment thereof recognizing a second target molecule.

### Claim 83 (depends on 82)

The targeting conjugate of claim 82, wherein:
i) the first target molecule is an immune checkpoint molecule, and the second target molecule is a tumor antigen;
ii) the first target molecule is a tumor antigen, and the second target molecule is an immune checkpoint molecule;
iii) the first target molecule and the second target molecule are both immune checkpoint molecules; or
iv) the first target molecule and the second target molecule are both tumor antigens.

### Claim 84 (depends on 76)

The targeting conjugate of claim 76, wherein A comprises a full-length antibody recognizing a first target molecule, an scFv, sdAb, or scFab recognizing a second target molecule, and the optional third cleavage site; wherein the optional third cleavage site is fused to the C-terminus of one or both heavy chains of the full-length antibody; and wherein
i) C1 is fused to the C-terminus of the optional third cleavage site at the C-terminus of the one or both heavy chains of the full-length antibody, and the scFv, sdAb, or scFab is fused to the C-terminus of C1 at the C-terminus of the one or both heavy chains of the full-length antibody; or
ii) C1 is fused to the C-terminus of the one or both heavy chains of the full-length antibody when the third cleavage site is not present, and the scFv, sdAb, or scFab is fused to the C-terminus of C1 at the C-terminus of the one or both heavy chains of the full-length antibody.

### Claim 85 (depends on 76)

The targeting conjugate of claim 76, wherein A comprises a full-length anti-PD-L1 antibody and the optional third cleavage site, wherein the optional third cleavage site is fused to the C-terminus of one or both heavy chains of the full-length anti-PD-L1 antibody; and wherein
i) C1 is fused to the C-terminus of the optional third cleavage site at the C-terminus of the one or both heavy chains of the full-length anti-PD-L1 antibody; or
ii) C1 is fused to the C-terminus of the one or both heavy chains of the full-length anti-PD-L1 antibody when the third cleavage site is not present.

### Claim 86 (depends on 75)

The targeting conjugate of claim 75, wherein the targeting conjugate comprises:
(a) a first polypeptide chain comprising from N terminus to C terminus: a first antibody heavy chain, a first optional cleavage site, a first conjugation site, and a first scFv, scFab, or sdAb;
(b) a second polypeptide chain comprising from N terminus to C terminus: a second antibody heavy chain, a second optional cleavage site, a second conjugation site, and a second scFv, scFab, or sdAb;
(c) a third polypeptide chain comprising a first antibody light chain;
(d) a fourth polypeptide chain comprising a second antibody light chain;
(e) a first therapeutic agent conjugated to the first conjugation site via a first linker;
(f) a second therapeutic agent conjugated to the second conjugation site via a second linker;
(g) a first oligonucleotide conjugated to the first polypeptide chain via a third linker; and
(h) a second oligonucleotide conjugated to the second polypeptide chain via a fourth linker.

### Claim 87

A targeting conjugate comprising a targeting moiety conjugated to a therapeutic agent or an oligonucleotide via a targeting moiety binding fragment (TBF), wherein the TBF comprises an amino acid sequence selected from any of SEQ ID NOs: 75-79 and 152.

### Claim 88 (depends on 75)

A pharmaceutical composition comprising a plurality of targeting conjugates of claim 75.

### Claim 89 (depends on 75)

A method of making a targeting conjugate of claim 75, comprising conjugating a therapeutic agent and/or an oligonucleotide to a targeting moiety.

### Claim 90 (depends on 88)

A method of treating a disease in an individual, comprising administering to the individual an effective amount of the pharmaceutical composition of claim 88.

### Claim 91

A targeting conjugate comprising a targeting moiety conjugated to a therapeutic agent, wherein the therapeutic agent comprises a structure selected from the group consisting of Formulae (1)-(7).
